Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 2:49 pm Sale | 2023-02-14 | 13G | The Carlyle Group Inc. CG | Capital World Investors | 2,217,000 0.600% | -17,098,259 (-88.52%) | Filing History |
| 2023-02-10 4:16 pm Purchase | 2022-12-31 | 13G | HilleVax, Inc. HLVX | Carlyle Group Inc. CG | 1,838,486 5.500% | 1,838,486 (New Position) | Filing History |
| 2023-02-10 4:16 pm Sale | 2022-12-31 | 13G | ZoomInfo Technologies Inc. GTM | Carlyle Group Inc. CG | 36,662,469 9.100% | -7,579,513 (-17.13%) | Filing History |
| 2023-02-10 4:14 pm Purchase | 2022-12-31 | 13G | Vaxcyte, Inc. PCVX | Carlyle Group Inc. CG | 2,070,724 2.600% | 2,070,724 (New Position) | Filing History |
| 2023-02-10 4:02 pm Sale | 2022-12-31 | 13G | The Carlyle Group Inc. CG | Rubenstein David M. | 29,249,644 8.100% | -2,000,000 (-6.40%) | Filing History |
| 2023-02-09 10:54 am Purchase | 2022-12-30 | 13G | The Carlyle Group Inc. CG | VANGUARD GROUP INC | 24,952,869 6.860% | 6,031,921 (+31.88%) | Filing History |
| 2023-02-08 2:29 pm Purchase | 2022-12-30 | 13G | The Carlyle Group Inc. CG | MORGAN STANLEY MS | 23,412,646 6.400% | 5,188,324 (+28.47%) | Filing History |
| 2023-01-31 4:15 pm Purchase | 2023-01-27 | 13D | Jasper Therapeutics, Inc. JSPR | Carlyle Group Inc. CG | 876,189 8.000% | 313,333 (+55.67%) | Filing History |
| 2023-01-23 5:15 pm Purchase | 2023-01-12 | 13D | Carlyle Credit Income Fund CCIF | Carlyle Group Inc. CG | 3,718,256 35.800% | 3,718,256 (New Position) | Filing History |
| 2022-12-20 4:30 pm Sale | 2022-12-16 | 13D | Soleno Therapeutics, Inc. SLNO | Carlyle Group Inc. CG | 0 0.000% | -1,224,571 (Position Closed) | Filing History |
| 2022-08-29 5:27 pm Purchase | 2022-08-17 | 13G | MKS Inc. MKSI | Carlyle Group Inc. CG | 8,482,732 12.800% | 8,482,732 (New Position) | Filing History |
| 2022-08-11 5:03 pm Purchase | 2022-08-01 | 13D | Exicure, Inc. XCUR | Carlyle Group Inc. CG | 57,086 5.700% | 57,086 (New Position) | Filing History |
| 2022-08-11 5:01 pm Purchase | 2022-08-01 | 13D | Vera Therapeutics, Inc. VERA | Carlyle Group Inc. CG | 2,970,156 11.100% | 2,970,156 (New Position) | Filing History |
| 2022-08-11 5:00 pm Purchase | 2022-08-01 | 13D | Adicet Bio, Inc. ACET | Carlyle Group Inc. CG | 2,152,959 5.400% | 2,152,959 (New Position) | Filing History |
| 2022-08-11 4:58 pm Purchase | 2022-08-01 | 13D | NuCana plc NCNA | Carlyle Group Inc. CG | 671 6.400% | 671 (New Position) | Filing History |
| 2022-08-11 4:56 pm Purchase | 2022-08-01 | 13D | Soleno Therapeutics, Inc. SLNO | Carlyle Group Inc. CG | 1,224,571 15.300% | 1,224,571 (New Position) | Filing History |
| 2022-08-11 4:55 pm Purchase | 2022-08-01 | 13D | eFFECTOR Therapeutics, Inc. EFTR | Carlyle Group Inc. CG | 193,196 11.700% | 193,196 (New Position) | Filing History |
| 2022-08-11 4:52 pm Purchase | 2022-08-01 | 13D | Reneo Pharmaceuticals, Inc. RPHM | Carlyle Group Inc. CG | 208,796 8.500% | 208,796 (New Position) | Filing History |
| 2022-08-11 4:50 pm Purchase | 2022-08-01 | 13D | Spruce Biosciences, Inc. SPRB | Carlyle Group Inc. CG | 1,802,518 7.700% | 1,802,518 (New Position) | Filing History |
| 2022-08-11 4:47 pm Purchase | 2022-08-01 | 13D | Jasper Therapeutics, Inc. JSPR | Carlyle Group Inc. CG | 562,856 15.400% | 562,856 (New Position) | Filing History |